Background
==========

Several proto-oncogenes have been demonstrated to be deregulated in human cancer. In particular, the development of the hematologic malignancies such as leukemia, is associated with aberrant expression or function of proto-oncogenes such as c-myc, evi-1, and c-abl. Many translocations with cytogenetic abnormalities that characterize leukemias involve rearrangement of transcription factors, including AML-ETO and Nup98-hox. Some of these leukemia-associated fusion proteins predict prognosis, e.g. t(8,21), t(15,17), and inv(16) are associated with a good prognosis in acute myeloid leukemia (AML) \[[@B1]\]. Approximately 50% of adult patients have been noted to have specific cytogenetic abnormalities. The overall survival of patients with AML is less than 50%. Since half of the patients diagnosed with AML have normal cytogenetic profiles, it is critical to understand the molecular pathways leading to leukemogenesis.

We identified that the cyclic AMP Response Element Binding Protein (CREB) was overexpressed in the majority of bone marrow samples from patients with acute leukemia \[[@B2],[@B3]\]. CREB is a leucine zipper transcription factor that is a member of the ATF/CREB family of proteins \[[@B4]-[@B6]\]. This transcription factor regulates proliferation, differentiation, and survival in a number of cell types, including neuronal and hematopoietic cells \[[@B4],[@B5]\]. CREB has been shown to be critical in memory and hippocampal development in mice \[[@B7],[@B8]\]. We previously described that CREB is phosphorylated at serine 133 downstream of signaling by the hematopoietic growth factor, Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) in myeloid cells \[[@B9]-[@B11]\]. We further demonstrated that CREB phosphorylation results from the activation of the Mitogen Activated Protein Kinase (MAPK) and pp90 Ribosomal S6 Kinase (pp90RSK) pathways in response to GM-CSF stimulation \[[@B9]\].

To understand the role of CREB in normal and neoplastichematopoiesis we investigated the expression of CREB in primary cells from patients with acute lymphoblastic (ALL) and myeloid leukemia and found that CREB was overexpressed in the majority of leukemia cells from patients with ALL and AML at the protein and mRNA levels \[[@B2],[@B3],[@B12]\]. Furthermore, overexpression of CREB was associated with a worse prognosis. We created CREB transgenic mice that overexpressed CREB in myeloid cells. These mice developed enlarged spleens, high monocyte count, and preleukemia (myeloproliferative disease) after one year. Bone marrow progenitor cells from CREB transgenic mice had increased proliferative capacity and were hypersensitive to growth factors compared to normal hematopoietic stems cells (HSCs). Overexpression of CREB in myeloid leukemia cell lines resulted in increased proliferation, survival, and numbers of cells in S phase \[[@B12]\]. Known target genes of CREB include the cyclins A1 and D \[[@B4],[@B5],[@B12],[@B13]\]. Both of these genes were upregulated in CREB overexpressing cells from mice and human cell lines \[[@B4],[@B5]\]. Thus, CREB is a critical regulator of leukemic proliferation and survival, at least in part, through its downstream target genes.

CREB target genes have been published on the website developed by Marc Montminy <http://natural.salk.edu/CREB/> based on ChIP chip data \[[@B14]\]. Additional CREB target genes were described by Impey et al. \[[@B15]\]. In their studies, serial analysis of chromatin occupancy (SACO) was performed by combining chromatin immunoprecipitation (ChIP) with a modification of Serial Analysis of Gene Expression (SAGE). Using a SACO library derived from rat PC12 cells, approximately 41,000 genomic signature tags (GSTs) were identified that mapped to unique genomic loci. CREB binding was confirmed for all loci supported by multiple GSTs. Of the 6302 loci identified by multiple GSTs, 40% were within 2 kb of the transcriptional start of an annotated gene, 49% were within 1 kb of a CpG island, and 72% were within 1 kb of a putative cAMP-response element (CRE). A large fraction of the SACO loci delineated bidirectional promoters and novel antisense transcripts \[[@B15]\]. These studies suggest that CREB binds many promoters, but only a fraction of the associated genes are activated in any specific lineage. We therefore set out to measure the functional targets of CREB in a hematopoietic model system.

Since CREB is overexpressed in bone marrow cells from patients with acute leukemia compared to normal HSCs, this provides a potential target for leukemia therapy. To this end, we stably transduced myeloid leukemia cells with CREB shRNAlentivirus\[[@B16]\]. CREB knockdown by 80% resulted in decreased proliferation and differentiation of both normal myeloid cells and leukemia cells *in vitro*and *in vivo*\[[@B16]\]. However, downregulation of CREB did not affect short-term or long-term engraftment of normal HSCs in bone marrow transplantation assays \[[@B16]\]. To understand the pathways downstream of CREB, we investigated genes that were differentially regulated in CREB shRNA transduced cells. In this paper, we report expression profiling of genes that were differentially regulated in CREB knockdown K562 myeloid leukemia cells and could be potential targets for development of new therapies for acute leukemia.

Methods
=======

Cell lines
----------

The following human leukemia cell lines were transduced with shRNAs: K562 (Iscoves + 10% FCS) and TF-1 (RPMI + 10%FCS + rhGM-CSF. Cells were cultured at 37°C, 5% CO2 and split every 3 to 4 days. Primary AML bone marrow samples were processed as previously described \[[@B12]\]. All human samples were obtained with approval from the Institutional Review Board and consents were signed, according to the Helsinki protocol.

shRNA sequence design and constructs
------------------------------------

The CREB specific shRNA sequences were selected and validated based on accepted parameters established by Tuschl et al. \[[@B17]-[@B19]\]<http://www.rockefeller.edu/labheads/tuschl/sirna.html>; CREB shRNA-1, CREB shRNA-2, CREB shRNA-3. Controls included empty vector, luciferaseshRNA, and scrambled shRNA. shRNA sequences are: CREB shRNA-1(5\'GCAAATGACAGTTCAAGCCC3\'), shRNA-2 (5\'GTACAGCTGGCTAACAATGG3\'), shRNA-3 (5\'GAGAGAGGTCCGTCTAATG3\'), LuciferaseshRNA (5\'GCCATTCTATCCTCTAGAGGA3\'), Scramble shRNA (5\'GGACGAACCTGCTGAGATAT3\'). Short-hairpin sequences were synthesized as oligonucleotides and annealed according to standard protocol. Annealed shRNAs were then subcloned into pSICO-R shRNA vectors from the Jacks laboratory at MIT \[[@B20]\]. The second generation SIN vector HIV-CSCG was used to produce human shRNA vectors \[[@B21]\].

Microarray analysis
-------------------

Total RNA (10 μg) was extracted from K562 cells transduced with vector alone or CREB shRNA was submitted to the UCLA DNA Microarray Facility. RNA samples were labeled and hybridized by standard protocol to Affymetrix Gene Chip Human Genome U133+ Array Set HG-U133A array. Gene expression values were calculated using the MAS5 software. The expression values are quantile normalized across all arrays. We obtained the expression profiles for a control set and CREB downregulated K562 cells. A t-test is performed between the two groups to identify significantly differentially regulated genes. The analysis was performed using Matlab (Mathworks, Inc.). We find a significant number of differentially expressed genes, which are either direct or indirect targets of CREB.

To further characterize the data we have aligned CREB binding data from chromatin immunoprecipitation studies with our expression data. The chromatin immunoprecipitation data was obtained from the website <http://natural.salk.edu/CREB/>\[[@B14]\]. To identify genes that are most significantly bound by CREB and differentially expressed in our knockdown experiment we first filtered genes by their fold change (greater than 1.5 or less than 0.7). Finally, we ranked genes according to the product of the binding and expression P value (jerry_bind_data.xls) (see Additional file [1](#S1){ref-type="supplementary-material"}).

We characterize these genes using three types of analyses: Ingenuity Pathway Analysis (IPA), Gene Ontology term enrichment analysis and tissue distribution. For the former analysis, we used the Ingenuity Pathways Analysis tool on the lists of significant downregulated genes. We then identified functions that were overrepresented among these genes. For the second, we used the DAVID website <http://david.abcc.ncifcrf.gov/home.jsp> to identify Gene Ontology terms that were enriched in the list.

Finally, we compute the tissue distribution of the 200 genes we identified as functional CREB targets. The tissue specific expression profiles of each gene are obtained from *HG_U133A/GNF1H and GNF1M Tissue Atlas Datasets*.\[[@B22]\]. We first compute the logarithm of the ratio of the expression intensity of each gene in each tissue, divided by its average intensity across all tissues. We then perform hierarchical clustering of both the genes and the tissues.

Quantitative Real-time PCR
--------------------------

K562 transduced with CREBshRNA(5 × 10^6^) were lysed in Trizol and stored at -80°C prior to RNA extraction. RNA extraction was performed according to a standard protocol supplied by the manufacturer (Invitrogen) and pellets were resuspended in RNAse free water. The cDNA was transcribed with a Superscript RT III based-protocol. DNAse treatment was not performed due to the selection of intron-spanning primers. Quantitative real-time PCR was performed with the SyberGreen reagent (Bio-Rad) in triplicates and analyzed by the standard curve method standardized to the housekeeping gene beta actin\[[@B23],[@B24]\].

Results and discussion
======================

Since CREB has pleiotropic effects on cell function and potentially activates several genes in hematopoietic and leukemia cells, we performed microarray analysis with total RNA isolated from K562 chronic myeloid leukemia cells transduced with CREB or control shRNA. The comparison of transcriptional profiles in wild type and CREB shRNA transduced K562 cells revealed a large number of differentially expressed genes (see Additional file [2](#S2){ref-type="supplementary-material"}). Among these genes, some are direct targets of CREB, while others are indirect targets. To infer which of these genes was potentially directly regulated by CREB, we combined the expression data with the ChIP-chip data of CREB bound promoters as demonstrated by Marc Montminy\[[@B14]\]. As was previously observed CREB binding sites are highly conserved across different tissues. However, these sites are activated by cAMP in a tissues specific manner. Therefore by combining these two datasets we attempted to uncover the functional CREB sites in hematopoietic tissues.

Our hypothesis for discovering functional CREB sites in hematopoietic cells is that if a gene is found to be differentially expressed in the CREB shRNA K562 transduced cells, and bound by CREB it is likely to be a direct target. To identify these genes we developed a metric that accounts for both the significance of the expression change and binding data for each gene (described in detail in Methods).

Since CREB has been described as both a transcriptional activator (when phosphorylated) and a repressor, we were interested in genes that were both up and downregulated in CREB shRNA transduced cells. The resulting rank ordered list allows us to sort genes by their likelihood of being functional CREB targets in K562 cells. It is difficult to determine, however, where to draw a threshold between the true and false targets. We have decided to restrict our analysis to the top several hundred targets that had both significant changes in expression and binding, as we deemed these to be highly enriched for true versus false targets. However, we do not claim that these are the only functional CREB targets in K562 cells, as the exact number of true targets is difficult to determine. The top down and upregulated genes revealed by this analysis are listed in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, and the full list is found in the supplementary materials.

###### 

Potential CREB target genes.

  Gene Name      Fold Change   CREB binding   CREB site   Gene Name   Fold Change   CREB binding   CREB site
  -------------- ------------- -------------- ----------- ----------- ------------- -------------- -----------
  DKFZP434G222   0.551725      3.883395       ht h        HSPC056     0.44548       1.892546       ht h
  ABCG2          0.479066      2.244422       ht h        HSU79303    0.573524      1.812829       ht
  ALDH2          0.5604        1.989872       none        ILVBL       0.675128      1.893295       ht h
  ALDH7A1        0.62012       2.051646       h           KIAA0103    0.682528      2.620283       ht h
  ALS2CR19       0.46208       1.788188       ht          HSU79303    0.573524      1.812829       ht
  ANC_2H01       0.659044      1.991467       ht h        ILVBL       0.675128      1.893295       ht h
  ANG            0.693535      3.287977       ht          KIAA0103    0.682528      2.620283       ht h
  APLP2          0.636685      1.219917       h           KIAA0141    0.689536      3.479426       h
  APPL           0.668234      1.391059       h           KIAA0408    0.595271      3.603389       none
  ARFD1          0.524897      2.336962       ht          KIAA0494    0.67838       5.420821       F
  BCL2L11        0.589894      3.191337       H h         KLF5        0.553523      2.062499       H
  BECN1          0.600243      1.151217       H h         KNSL8       0.468603      7.854334       HT ft
  BMX            0.315984      1.072006       none        KPNA5       0.562667      2.859517       none
  C20orf133      0.635849      2.420642       h           LANCL1      0.647544      1.020319       none
  C6orf67        0.610619      2.665053       h           LOC51668    0.500097      1.062053       ht h
  CA2            0.592202      1.082939       ht          LOC51762    0.599397      3.307553       ht h
  CALB2          0.671562      1.894443       h           LYPLA3      0.664078      2.379015       HT h
  CCDC2          0.533032      1.529166       none        MAF         0.597194      2.383458       FT
  CENPE          0.306986      3.736367       FT ht       MAPKAPK5    0.699356      2.053184       FH
  CGI-77         0.664435      4.334985       H ht h      MDM2        0.468991      2.523732       none
  CLDN18         0.566707      4.30699        ht h        MGC15419    0.617252      3.032433       h
  CNN1           0.670957      1.150221       F ht h      MPHOSPH1    0.423771      3.535138       ht h
  CREB1          0.382751      1.816762       HT H ht h   MSH2        0.592302      3.203985       h
  CSPG6          0.573523      3.082765       h           MVD         0.632896      3.854905       ht h
  CUL5           0.683117      2.073118       H ht h      MYL4        0.69963       1.010099       h
  DBP            0.67969       2.805267       ft ht       NEFL        0.343403      2.413823       HT h
  DES            0.521516      1.509794       ht h        NFKBIL1     0.695019      4.072353       ht
  DIS3           0.692573      3.837304       HT ht       NIPSNAP1    0.679129      1.215594       h
  DNCI1          0.673721      2.195167       none        NOX3        0.455479      2.60292        h
  DNMT3A         0.679821      1.035348       h           NR4A3       0.543361      5.002146       HT H h
  DSIPI          0.40458       2.546212       HT          NUDT5       0.673003      2.561752       h
  DUSP19         0.674195      2.225933       none        NUMB        0.675667      1.014954       HT ht
  EIF2S1         0.631867      1.075696       H ht h      PDE6B       0.66696       2.699363       h
  EIF2S2         0.644661      3.313634       ht h        PEX12       0.694707      6.199684       h
  ESRRBL1        0.67914       4.633352       FH h        PFDN4       0.507631      2.196535       none
  FBXO22         0.688756      2.206273       ht          PHC1        0.672187      1.053985       HT
  FECH           0.516446      1.045191       h           PKD2L2      0.513894      2.249593       h
  FECH           0.658471      1.045191       h           PLAA        0.603854      9.235476       none
  FLJ10853       0.622952      3.981514       H ht        PPP1R2      0.568734      2.04019        ft
  FLJ10858       0.668758      1.523113       none        PRDX3       0.615229      1.847784       none
  FLJ10904       0.54026       1.085341       none        PSAT1       0.47554       2.492965       ht
  FLJ11011       0.610253      3.387879       ht h        PSMAL/GCP   0.68221       1.341117       none
  FLJ11342       0.683482      2.617474       ht          PTGS2       0.684401      3.057276       ht h
  FLJ11712       0.62618       2.776373       ht          RAB31       0.698664      1.12667        ht
  FLJ13491       0.633125      3.268155       none        RB1CC1      0.533475      1.390318       none
  FLJ20130       0.640787      2.766588       h           RFC3        0.577787      6.745001       FH ht
  FLJ20331       0.681859      8.752576       H           RHEB        0.682202      3.47317        HT H h
  FLJ20333       0.690542      1.946262       ht h        RNASE4      0.436168      2.975774       ht h
  FLJ20509       0.691949      1.96435        none        SARS2       0.692149      5.455469       H h
  FLJ23233       0.471676      1.517415       none        SBBI26      0.683312      6.75719        H
  FOXD1          0.593522      5.160553       HT ht       SDP35       0.502432      2.320591       h
  GCAT           0.656744      2.122675       ht h        SERPINI1    0.31594       3.277692       ht
  GCHFR          0.676365      2.188753       ht h        SHMT1       0.658252      1.127084       ht h
  GFI1B          0.671179      0.999255       h           SILV        0.662805      2.130617       H
  GMPR           0.672975      1.149663       ht          SLC11A2     0.684325      1.842417       none
  GOLGA4         0.567882      2.939327       ht h        SLC22A5     0.657746      1.64513        none
  GPNMB          0.410992      1.004344       none        SLC27A6     0.547039      1.029816       ht
  GRHPR          0.68706       2.454475       H ht        SLC2A4      0.507466      2.273185       ht h
  H2BFS          0.591569      2.358423       ht          SLC39A8     0.201136      1.004832       none
  HBE1           0.639376      0.947159       h           SLC4A7      0.532067      1.262531       ht
  HDGFRP3        0.65013       1.208322       none        SMARCA1     0.519982      1.056916       HT ht
  HDGFRP3        0.668211      1.208322       none        SMC2L1      0.596288      2.916083       ht h
  HEXA           0.54467       2.622927       none        SRI         0.671893      0.826457       ht
  HIST1H1C       0.590374      1.983514       h           STK16       0.680797      6.555535       H h
  HIST1H2AD      0.66909       4.768013       ht h        SULT1C2     0.599235      3.511947       f h
  HIST1H2AI      0.542518      2.801688       H ht h      SURB7       0.498245      1.598812       ht
  HIST1H2AJ      0.696531      3.066865       ft ht h     SYN1        0.696375      3.016534       F h
  HIST1H2AL      0.602018      2.600144       FHT ht h    TAF1A       0.589389      2.689618       none
  HIST1H2BB      0.590821      1.782458       ht h        TBC1D7      0.692755      1.281463       ht
  HIST1H2BD      0.674855      3.111055       HT ht h     TCTE1L      0.368312      2.475611       ht
  HIST1H2BE      0.546621      2.34815        ht          TFDP2       0.670657      1.016413       ht
  HIST1H2BF      0.543665      1.985466       ht          TGDS        0.67197       1.523411       none
  HIST1H2BH      0.617917      2.04185        none        THRB        0.670555      2.256453       H ht h
  HIST1H2BI      0.585897      1.443622       ht          TMEM14A     0.656093      1.175355       ht h
  HIST1H2BJ      0.493823      5.335159       HT ht h     TOM1        0.64031       3.221137       h
  HIST1H2BM      0.687469      3.533372       ft ht h     TXN2        0.689274      1.893339       H ht h
  HIST1H2BO      0.618862      4.014214       ht h        UBE2B       0.663194      3.652863       H ht h
  HIST1H3B       0.556438      4.260113       ft ht       VRK1        0.650583      1.000406       h
  HIST1H3H       0.641946      2.647758       H ht h      WASPIP      0.572355      1.01892        none
  HIST1H4E       0.608257      2.458831       FT h        WDHD1       0.624889      4.984045       H ht h
  HIST1H4I       0.612088      2.068983       ht          WWOX        0.671866      1.882778       h
  HIST2H2AA      0.560962      4.032876       ht          ZNF134      0.677481      2.726853       ht h
  HLA-DRA        0.365141      3.086303       ht h        ZNF222      0.5618        4.09755        ht h
  HLXB9          0.667926      1.006593       none        ZNF230      0.410725      3.76825        ht h
  HS2ST1         0.694429      1.032562       ht h        ZNF235      0.38371       2.959812       none
  HSBP1          0.671929      1.891961       ht h                                                 

Top down-regulated genes that show significant CREB binding and changes in expression in the CREB knockdown cells. The detailed criteria for selecting these genes are described in the methods section. For each grouping of genes, from left to right, column 1 shows the gene symbols, column 2 the ratio of the expression change in wild type versus knockdown, column 3 the CREB binding ratio and column 4 the presence of CREB binding motifs. The key for column 4 is as follows: F is a full CREB motif (TGACGCTA) that is conserved from human to mouse, while f is not conserved, H is a conserved CREB half motif (TGACG or CGTCA), while h is not conserved, and T is the conserved presence of a TATA motif less than 300 base pairs downstream of the CREB motif, while t is not conserved.

###### 

Potential CREB target genes.

  Gene Name   Fold Change   CREB binding   CREB site    Gene Name   Fold Change   CREB binding   CREB site
  ----------- ------------- -------------- ------------ ----------- ------------- -------------- -----------
  ACOX1       2.110674      2.911283       H ht         LDLR        1.678587      1.525499       ht
  ADAT1       1.410234      3.769574       ht f h       LGALS3BP    2.131291      3.615437       none
  APEH        1.400261      2.527266       h            LIM         1.696177      1.097432       none
  APPBP2      1.486616      2.151867       H ht h       LIM         1.849989      1.097432       none
  ARHB        2.758453      2.77377        H ht         LRRFIP1     1.941595      1.122307       h
  ATP6V1A     1.446867      3.016595       HT ht h      METAP2      1.916632      2.635425       ht
  BCL6        1.640646      6.084626       HT ht        METTL2      1.593867      3.474639       none
  BDKRB2      1.600927      2.601219       none         MGC2731     1.588545      2.80081        HT h
  BTN3A2      1.465264      3.426679       ht           MGC4054     1.502743      2.777966       ht
  C20orf12    1.511854      3.12999        h            MOCS3       1.796255      5.213295       none
  C20orf121   1.456022      3.532969       H            MRPS10      1.410471      1.834794       ht f
  C20orf172   1.463616      4.659037       H h          NCOA3       1.495237      2.715807       ht
  C20orf23    1.528396      2.622103       none         NDRG1       2.030896      2.312257       ht h
  CD44        9.531947      1.335178       ht h         NEDF        1.567662      4.268912       ft ht
  CDH12       3.296441      1.178959       none         NPR2L       1.618864      6.397355       ht h
  CDKAL1      1.735322      3.445022       none         ODZ1        1.448279      2.310975       ht
  CDKN1A      2.216725      1.778747       H ht h       OPA3        1.474233      7.631458       FHT ht h
  CELSR3      1.546375      3.175919       H ht         OTC         1.693003      4.881484       ht
  CENPF       1.415064      2.654622       ht           PAFAH2      1.67217       4.584628       none
  CHRNB1      1.55045       1.412576       H h          PAFAH2      1.631066      4.584628       none
  CLECSF2     1.747573      1.251667       none         PHC3        1.42261       1.747154       ht
  CML2        1.47905       3.427882       ht           PHLDA1      3.92008       2.003171       h
  COL15A1     2.56792       1.394566       none         PLAT        1.668223      1.95203        none
  CREM        1.793497      3.67068        H            PLEKHB2     1.568395      4.611748       f
  CRKL        1.690269      3.051845       H h          PPARGC1     2.268458      2.972107       HT F ht h
  CSMD1       1.647116      1.61907        ht           PPFIBP1     1.852526      2.550633       ht h
  CTMP        1.548763      3.386235       none         PPP1R10     1.870902      2.447557       H h
  DBT         1.518604      4.292329       none         PPP1R3B     1.693114      1.622596       h
  DCLRE1C     1.41992       3.010944       none         PSMAL/GCP   1.506527      2.707076       none
  DDOST       1.582101      2.508459       ht           RAB7L1      1.638378      1.15364        ht h
  DDX3X       1.817009      3.42975        none         RABL2B      1.486054      2.496157       h
  DEGS        1.488221      1.464348       none         RASSF1      1.431271      4.04395        none
  DIAPH1      1.412484      2.96506        none         RBL1        1.529652      2.451247       h
  DUSP1       1.578824      2.102797       FT HT ht h   REL         1.944847      1.143935       H h
  EGR2        5.148023      2.036633       HT ht h      RHOBTB3     1.63057       2.813465       none
  EIF5        1.422558      4.208549       ht h         RIOK3       1.40951       2.008376       none
  ELK1        1.405171      4.088789       ht           RNASE6PL    1.561704      2.252099       ht
  ENC1        1.957151      1.549567       h            RNF32       1.954396      1.603905       H ht
  F2R         1.804785      1.098488       ht h         SAS         1.768493      7.735178       HT ht h
  FAM13A1     1.780869      2.014276       none         SERPINB9    2.244605      1.418097       ht h
  FAT         2.00051       1.816506       F ht         SFPQ        1.477265      3.428149       ht
  FKBP14      1.78994       3.042488       ht           SHARP       1.558516      1.078188       H ht
  FLJ10781    1.463332      1.113364       ht h         SLC31A1     1.491104      3.803168       FH ht
  FLJ10803    1.726196      2.63943        ht           SLC35E3     1.716026      1.969928       ht
  FLJ11029    1.422001      3.085667       ht h         SLC38A2     1.497716      1.914154       H ht
  FLJ11151    2.413055      1.840398       h            SLC39A6     1.477678      3.119807       h
  FLJ20507    1.730068      2.922871       H ht h       SMA3        1.414595      2.654203       ht
  FOSL1       2.220086      1.929543       HT ht h      SMARCF1     1.537978      1.046929       none
  FRSB        1.423607      2.982919       ht           SNAP29      1.521481      2.454502       h
  FXC1        1.423019      5.02095        HT H ht      SON         1.42477       4.933417       H
  GALNS       1.772331      2.592543       h            SPG4        1.413533      3.160161       none
  GCA         1.690161      2.92801        H h          SUFU        1.661693      2.275704       ht h
  GTF2H3      1.593421      10.587057      H            TAP1        1.435113      3.105625       H h
  GYS1        1.418699      2.559154       h            TIGD6       1.772719      3.636168       h
  HBS1L       1.475369      3.891767       ht           TIMP1       1.791155      1.848154       HT h
  HIP1        1.537214      2.114631       ht h         TNFRSF21    1.498482      2.635088       ht
  HLA-C       1.429002      3.2916         h            TP53AP1     1.527339      3.493111       ht h
  HSPG2       1.708361      1.453039       none         TPM4        2.201468      1.33368        H ht
  ICAM1       2.20462       1.198603       ht h         TRIM26      1.400065      6.12308        ht
  ID1         1.521685      2.3068         FT ht        TSSC3       1.879281      2.01021        H ht h
  IDS         1.508286      1.1848         h            TTF1        1.513382      3.461645       ht h
  IER5        1.66867       2.847755       HT ht        TUBA3       1.481437      2.500545       none
  IL10RA      1.64246       2.830231       f            U2AF1L1     2.758542      3.548509       ht
  IL10RB      1.410005      1.192048       ht h         U5-116KD    2.223148      2.779884       h
  IL1R1       1.812093      1.329947       ht           USP2        2.35423       3.920336       HT H h
  IL6         1.980266      1.460112       HT ht        VPS4B       1.474465      6.693871       H ht
  IL6ST       1.54702       3.418269       none         YME1L1      1.441837      1.843132       F ht h
  INPP1       2.071508      1.550135       ht h         ZFP37       1.572207      4.659572       ht h
  ITGA5       2.028008      1.315131       none         ZNF142      1.50914       3.028386       h
  JM4         1.606813      2.392743       HT h         ZNF155      1.69746       4.195939       none
  KIAA0266    1.504796      2.986155       none         ZNF189      1.625836      4.104303       ht h
  KIF14       1.453888      4.181899       none         ZNF221      1.777122      3.569536       none
  KIF3B       1.623133      1.560467       none         ZNF324      1.488601      4.205703       h
  LCMT2       1.587221      2.338943       H ht h                                                

Top up-regulated genes that show significant CREB binding and changes in expression in the CREB knockdown cells. The detailed criteria for selecting these genes are described in the methods section. The column descriptions are the same as in Table [1](#T1){ref-type="table"}.

Genes within the downregulated list were BECLIN 1, UBE2B. Both these genes have a cAMP responsive element binding site(s) in their promoters. These genes were selected for further validation because they are known to be involved in autophagy/apoptosis (BECLIN 1), cell cycle/DNA repair (UBE2B) \[[@B25]-[@B28]\]. Quantitative real time-polymerase chain reaction (qRT-PCR) with mRNA from AML cell lines (K562 and TF-1) and primary leukemic blasts from a patient with M4-AML was performed. UBE2B expression was significantly reduced in CREB shRNA transduced TF-1 and K562 myeloid leukemia cells compared to controls (Figure [1](#F1){ref-type="fig"}, p \< 0.05). BECLIN and UBE2B were downregulated in primary AML cells transduced with CREB shRNA (Figure [1](#F1){ref-type="fig"}, p \< 0.05).

![**Expression of potential target genes downstream of CREB in myeloid leukemia cells. Primers specific for the UBE2B, BECLIN1, and CREB genes were generated and utilized for quantitative real-time PCR by SyberGreen method (Bio-Rad Inc.)** Relative gene expression normalized to the housekeeping gene actin is shown for the following transduced cells: (A) K562 myeloid leukemia cells, (B) TF-1 myeloid leukemia cells, and (C) Human AML-M4 blasts.](1471-2407-8-264-1){#F1}

Having confirmed the validity of our microarray results in these two test cases we set out to characterize the function of the complete list of CREB target genes using two annotation schemes. The first utilizes the annotation contained in the Ingenuity Pathway Analysis software (IPA). This analysis showed that there is a significant enrichment for cell cycle (P \< 1e-3) and cancer (P \< 1e-3) genes. The full list of genes associated with cancer is shown in Table [3](#T3){ref-type="table"}. Many of these genes regulate cell cycle, signaling, DNA repair, or metabolism, which are consistent with previously published results \[[@B5],[@B15]\]. Furthermore, the role of CREB in the pathogenesis of leukemias has also been described in the literature \[[@B2],[@B3],[@B12],[@B29]\].

###### 

The subset of CREB target genes associated with cancer according to Ingenuity Pathways Analysis.

  Name                         Location              Type                                Drugs
  ---------------------------- --------------------- ----------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Downregulated Cancer Genes                                                             
  ABCG2                        Plasma Membrane       transporter                         
  ANG                          Extracellular Space   enzyme                              
  BCL2L11                      Cytoplasm             other                               
  BECN1                        Cytoplasm             other                               
  BMX                          Cytoplasm             kinase                              
  CA2                          Cytoplasm             enzyme                              methazolamide, hydrochlorothiazide, acetazolamide, trichloromethiazide, dorzolamide, chlorothiazide, dorzolamide/timolol, brinzolamide, chlorthalidone, benzthiazide, sulfacetamide, topiramate
  CENPE                        Nucleus               other                               
  CNN1                         Cytoplasm             other                               
  CREB1                        Nucleus               transcription regulator             
  CUL5                         Nucleus               ion channel                         
  GFI1B                        Nucleus               transcription regulator             
  KLF5                         Nucleus               transcription regulator             
  MDM2 (includes EG:4193)      Nucleus               transcription regulator             
  MPHOSPH1                     Nucleus               enzyme                              
  MSH2                         Nucleus               enzyme                              
  MVD                          Cytoplasm             enzyme                              
  NR4A3                        Nucleus               ligand-dependent nuclear receptor   
  NUMB                         Plasma Membrane       other                               
  PPP1R2                       Cytoplasm             phosphatase                         
  PTGS2                        Cytoplasm             enzyme                              acetaminophen/pentazocine, acetaminophen/clemastine/pseudoephedrine, aspirin/butalbital/caffeine,
  RB1CC1                       Nucleus               other                               
  SILV                         Plasma Membrane       enzyme                              
  SMC2                         Nucleus               transporter                         
  SMC3                         Nucleus               other                               
  TFDP2                        Nucleus               transcription regulator             
  THRB                         Nucleus               ligand-dependent nuclear receptor   3,5-diiodothyropropionic acid, amiodarone, thyroxine, L-triiodothyronine
  UBE2B                        Cytoplasm             enzyme                              
  VRK1                         Nucleus               kinase                              
  WWOX                         Cytoplasm             enzyme                              
  Upregulated cancer Genes                                                               
  ACOX1                        Cytoplasm             enzyme                              
  ARID1A                       Nucleus               transcription regulator             
  BCL6                         Nucleus               transcription regulator             
  BDKRB2                       Plasma Membrane       G-protein coupled receptor          anatibant, icatibant
  CD44                         Plasma Membrane       other                               
  CDKN1A                       Nucleus               kinase                              
  COL15A1                      Extracellular Space   other                               collagenase
  CREM                         Nucleus               transcription regulator             
  CRKL                         Cytoplasm             kinase                              
  DCLRE1C                      Nucleus               enzyme                              
  DEGS1                        Plasma Membrane       enzyme                              
  DIAPH1                       Cytoplasm             other                               
  DUSP1                        Nucleus               phosphatase                         
  EGR2                         Nucleus               transcription regulator             
  ELK1                         Nucleus               transcription regulator             
  ENC1                         Nucleus               peptidase                           
  F2R                          Plasma Membrane       G-protein coupled receptor          chrysalin, argatroban, bivalirudin
  FOSL1                        Nucleus               transcription regulator             
  HIP1                         Cytoplasm             other                               
  HSPG2 (includes EG:3339)     Plasma Membrane       other                               
  ICAM1                        Plasma Membrane       transmembrane receptor              
  ID1                          Nucleus               transcription regulator             
  IL6                          Extracellular Space   cytokine                            tocilizumab
  IL1R1                        Plasma Membrane       transmembrane receptor              anakinra
  IL6ST                        Plasma Membrane       transmembrane receptor              
  ITGA5                        Plasma Membrane       other                               
  KIF14                        Cytoplasm             other                               
  METAP2                       Cytoplasm             peptidase                           PPI-2458
  NCOA3                        Nucleus               transcription regulator             
  NDRG1                        Nucleus               kinase                              
  PHLDA1                       Cytoplasm             other                               
  PLAT                         Extracellular Space   peptidase                           
  RASSF1                       Nucleus               other                               
  RBL1                         Nucleus               other                               
  REL                          Nucleus               transcription regulator             
  RHOB                         Cytoplasm             enzyme                              
  SERPINB9                     Cytoplasm             other                               
  SUFU                         Nucleus               transcription regulator             
  TIMP1                        Extracellular Space   other                               
  TNFRSF21                     Plasma Membrane       other                               
  USP2                         Cytoplasm             peptidase                           

Column 1 is the gene name, column 2 the localization, column 3 is a description of the protein function and column 4 are compounds that target the protein.

IPA also allows us to study CREB target genes in the context of protein-protein interactions networks. A network for downregulated genes interacting with CREB is shown in Figure [2](#F2){ref-type="fig"}, with a subset of the downregulated targets shown in grey, while other genes not in the target list that interact with these, shown in white. Here we see that there is prior literature supporting our analysis that CREB1 regulates PTGS2 (COX2), NR4A3 and TOM1, as depicted by the blue lines. Interestingly, COX2 is an important drug target, and suggests that commonly used COX2 inhibitors may provide a target for acute leukemia.

![**A network depicting interactions between direct CREB targets (shown in grey) and proteins that these interact with (shown in white).** PTGS2, NR4A3 and TOM1 are direct CREB targets whose regulation by CREB was previously described in the literature (clue lines). PTGS2 (COX2) emerges as a central player in this network, and is thus implicated as a potential regulator of leukemias.](1471-2407-8-264-2){#F2}

The second analysis that we performed used the terms from Gene Ontology to identify common characteristics among the top K562 CREB targets. Here we find the striking and unexpected result that ten percent of the downregulated targets code for histone genes (P \< 1e-10, Table [4](#T4){ref-type="table"}). We also performed an analysis of the top upregulated genes but did not find any significant GO terms. Although there is some prior literature indicating that CREB or CREB-related pathways may play a role in regulating histone modifications primarily through the histone acetylase CREB Binding Protein (CBP)\[[@B5],[@B30],[@B31]\], the fact that CREB directly regulates the transcription of histone genes in these cells is unexpected.

###### 

Gene Ontology terms that are enriched among the top CREB targets.

  Category        Term                                                         Count   \%       PValue
  --------------- ------------------------------------------------------------ ------- -------- ----------
  GOTERM_CC_ALL   nucleosome                                                   11      6.88%    6.22E-10
  GOTERM_CC_ALL   chromosome                                                   17      10.62%   2.39E-09
  GOTERM_BP_ALL   nucleosome assembly                                          11      6.88%    6.60E-09
  GOTERM_CC_ALL   chromatin                                                    13      8.12%    7.56E-09
  GOTERM_BP_ALL   chromatin assembly                                           11      6.88%    1.66E-08
  GOTERM_BP_ALL   protein complex assembly                                     15      9.38%    2.19E-07
  GOTERM_BP_ALL   chromatin assembly or disassembly                            11      6.88%    3.84E-07
  GOTERM_BP_ALL   chromosome organization and biogenesis                       15      9.38%    5.56E-07
  GOTERM_BP_ALL   chromosome organization and biogenesis (sensu Eukaryota)     14      8.75%    1.63E-06
  GOTERM_CC_ALL   membrane-bound organelle                                     75      46.88%   1.93E-06
  GOTERM_CC_ALL   intracellular membrane-bound organelle                       74      46.25%   4.63E-06
  GOTERM_CC_ALL   organelle                                                    83      51.88%   5.39E-06
  GOTERM_MF_ALL   DNA binding                                                  38      23.75%   6.17E-06
  GOTERM_BP_ALL   cellular physiological process                               118     73.75%   8.86E-06
  GOTERM_BP_ALL   establishment and/or maintenance of chromatin architecture   12      7.50%    1.02E-05
  GOTERM_CC_ALL   intracellular organelle                                      82      51.25%   1.28E-05
  GOTERM_BP_ALL   DNA packaging                                                12      7.50%    1.38E-05
  GOTERM_BP_ALL   organelle organization and biogenesis                        22      13.75%   1.59E-05
  GOTERM_CC_ALL   nucleus                                                      56      35.00%   2.46E-05
  GOTERM_BP_ALL   DNA metabolism                                               19      11.88%   2.63E-05

Column 1 is the ontology used (BP is biological process, CC is cellular localization and MF is molecular function), column 2 is the term, column 3 is the number of genes in the target list associated wit the term, column 4 is the percentage of genes in the target list associated with the term and column 5 is the P value for observing this number genes associated with the term.

To further validate the hypothesis that CREB is an activator of these 20 histone genes, we utilized previously published analyses of the gene promoters to identify consensus CREB binding sequences. The results shown in Table [1](#T1){ref-type="table"} demonstrate that nearly all the histone genes contain CREB half sites along with a TATA box in the vicinity of these. Thus three lines of evidence support the assignment of these 20 histone genes as CREB targets in K562 cells: expression, binding and sequence based.

We examined the distribution of expression of these 20 histone genes across human tissues. The expression data were obtained from the GNF body atlas. We were able to extract expression profiles for 81 histone genes contained in the human genome. Fifteen of these overlapped with the 20 histone CREB targets. We show the expression of all 81 histone genes in Figure [3](#F3){ref-type="fig"}, where the identity of the 15 CREB target genes is shown in the last row. We see that the 15 genes are clustered into two groups containing more than one gene, with a third group consisting of a single histone HIST1H1C. One of the groups contains histones that are broadly expressed across human tissues, and particularly in all hematopoietic tissues. The second group is instead expressed in a very narrow range of tissues including K562 cells, bone marrow, prostate and thymus.

![**The tissue specific expression of histone genes. Each row of the figure represents a tissue from the GNF Body Atlas (see methods).**We show only the top 30 tissues with highest variance of expression of histone genes. Each column represents a histone gene. We use hierarchical clustering to order the rows and columns according to their similarity. Red indicates that the gene is over expressed relative to its mean expression levels across all tissues, and green that it is under expressed. The histone genes that we identify as direct targets of CREB are shown in red in the last row of the figure. We see that many of these are only expressed in a small subset of rapidly dividing tissues along with K562 cells.](1471-2407-8-264-3){#F3}

We examined the expression of three histones that are putative targets of CREB by real time PCR with mRNA from K562, TF-1, and primary cells from patients with AML. The three histones selected were based on our microarray analyses. Our results demonstrated a statistically significant decrease in histonesHIST1H2Bj, HIST1H3B, and HIST2H2AA in K562 and TF-1 cells (Figure [4](#F4){ref-type="fig"}). Interestingly, in primary cells from a patient with AML, only HIST1H3B and HIST2H2AA, but not HIST1H2BJ expression was decreased with CREB knockdown. These results suggest that histones are differentially expressed in AML and that specific histones are potential targets of CREB. This analysis supports the hypothesis that CREB regulates a subset of histone genes that are normally expressed in a small set of rapidly dividing tissues. These genes are presumably aberrantly activated in K562 and other leukemia cells, and could potentially contribute to the malignant phenotype.

![**Expression of target histone genes is decreased in CREB knockdown myeloid leukemia cells. Primers specific for HIST1H2BJ, HIST1H3B, and HIST2H2AA were generated and utilized for quantitative real-time PCR by the SYBR Green method (Applied Biosystems).** Relative gene expression normalized to the housekeeping gene actin is shown for the following transduced cells: (A) K562 myeloid leukemia cells, (B) TF-1 myeloid leukemia cells, and (C) primary AML cells.](1471-2407-8-264-4){#F4}

Conclusion
==========

We have identified a high confidence list of CREB target genes in K562 myeloid leukemia cells. Several important CREB target genes that function in DNA repair, signaling, oncogenesis, and autophagy were identified. These genes provide potential mechanisms by which CREB contributes to the pathogenesis of acute leukemia. Expression of the genes beclin-1 and ube2b was found to be decreased in myeloid leukemia cell lines and primary AML cells in which CREB was downregulated. In addition, we speculate that CREB may have more global effects on transcription, primarily through the regulation of histone genes thereby altering the regulation of DNA replication during the cell cycle.
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